The Multiple Sclerosis Society of Canada has funded Canada’s first stem cell clinical trial to treat multiple sclerosis, conducted by researchers at the University of Ottawa. The trial, called MESCAMS [Mesenchymal Stem Cell Therapy for Canadian MS patients], will comprise MSC infusions to the central nervous system to utilize their ability to regulate autoimmune attacks and reduce inflammation in 40 MS patients. Continue reading
Researchers at the Cedars-Mt. Sinai Regenerative Medicine Institute, led by Dr. Robert H. Baloh, have devised a method to study and develop potential treatments for Amyotrophic Lateral Sclerosis [ALS] by utilizing patients’ stem cell-derived neurons. In an example of what is referred to as translational genomics, researchers extract autologous (the patient’s own) stem cells, correct the defective gene causing the disease, and then, in a potential treatment protocol, transplant the cells back into the patient to reverse neural degeneration. Continue reading
A team of researchers from the University of Michigan and the University of Emory reported positive results from a phase 1 clinical study utilizing stem cells to treat amyotrophic lateral sclerosis [ALS], Lou Gehrig’s disease. In addition to verifying the safety of the new procedure, the trial revealed some progress in preventing further disease damage to the motor nerves by improving their cellular environment. Continue reading
Scientists in the US (UC, UCSD) and China (Wuhan) have found a way to convert stem cells into functional neurons. The researchers were able to suppress an RNA-binding protein, inducing the stem cells to become neurons. This gives hope for a treatment for neurodegenerative diseases such as Huntington’s, Parkinson’s, Alzheimer’s, Multiple Sclerosis, and Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease), which will afflict one in four Americans over their lifetime.